Patrick A. Brown

Donald H. Mahoney1
Michelle A. Rudek1
Mignon L. Loh1
Amaro N. Taylor-Weiner1
Sophie L. Archambeault1
1Donald H. Mahoney
1Michelle A. Rudek
1Mignon L. Loh
1Amaro N. Taylor-Weiner
1Sophie L. Archambeault
Learn More
  • Elliot Stieglitz, Amaro N. Taylor-Weiner, Tiffany Y. Chang, Laura C. Gelston, Yong-Dong Wang, Tali Mazor +41 others
  • 2015
Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative neoplasm (MPN) of childhood with a poor prognosis. Mutations in NF1, NRAS, KRAS, PTPN11 or CBL occur in 85% of patients, yet there are currently no risk stratification algorithms capable of predicting which patients will be refractory to conventional treatment and could therefore be candidates(More)
A large number of medical errors can be attributed to errors in diagnosis. A diagnosis reminder system such as Isabel may lessen the risk of diagnostic error by providing a checklist of possible diagnoses. For this project, resident physicians used Isabel to work through a set of six simulated patient cases. The system had a positive effect on the mean(More)
  • Jennifer M. Fox, James R. Moynihan, Bryan T. Mott, Jennifer R. Mazzone, Nicole M. Anders, Patrick A. Brown +6 others
  • 2016
Artemisinins, endoperoxide-containing molecules, best known as antimalarials, have potent antineoplastic activity. The established antimalarial, artesunate (AS), and the novel artemisinin-derived trioxane diphenylphosphate dimer 838 (ART-838) inhibited growth of all 23 tested acute leukemia cell lines, reduced cell proliferation and clonogenicity, induced(More)
  • 1